Outcomes of the 340B Drug Pricing Program
Open Access
- 3 November 2023
- journal article
- review article
- Published by American Medical Association (AMA) in JAMA Health Forum
- Vol. 4 (11) , e233716
Abstract
The 340B Drug Pricing Program was created in 1992 to support safety net hospitals and clinics caring for low-income and underserved populations by discounting the cost of outpatient drugs.1 The revenue from dispensing these discounted drugs allows these entities to reach more patients, provide more health care services and programs, and subsidize uncompensated care.Keywords
This publication has 33 references indexed in Scilit:
- Understanding scoping reviewsJournal of the American Association of Nurse Practitioners, 2017
- A scoping review on the conduct and reporting of scoping reviewsBMC Medical Research Methodology, 2016
- Pricing in the Market for Anticancer DrugsJournal of Economic Perspectives, 2015
- The 340B Discount Program: Outpatient Prescription Dispensing Patterns Through Contract Pharmacies In 2012Health Affairs, 2014
- The 340B Drug Discount Program: Hospitals Generate Profits By Expanding To Reach More Affluent CommunitiesHealth Affairs, 2014
- A different view of the 340B program.2014
- Protect the 340B drug program.2014
- The impact of patient assistance programs and the 340B Drug Pricing Program on medication cost.2014
- Cost Consequences of the 340B Drug Discount ProgramJAMA, 2013
- Scoping studies: towards a methodological frameworkInternational Journal of Social Research Methodology, 2005